Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
$2.27
-0.0400 (-1.73%)
At Close: May 10, 2024
Forecast Earnings Dividends Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $1.31 $4.00 Friday, 10th May 2024 CYCC stock ended at $2.27. This is 1.73% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 6.60% from a day low at $2.16 to a day high of $2.30.
90 days $1.31 $4.00
52 weeks $1.31 $13.20

Historical Cyclacel Pharmaceuticals prices

Date Open High Low Close Volume
Feb 03, 2020 $0.680 $0.700 $0.655 $0.660 114 723
Jan 31, 2020 $0.703 $0.720 $0.650 $0.653 183 063
Jan 30, 2020 $0.720 $0.750 $0.700 $0.700 205 651
Jan 29, 2020 $0.728 $0.770 $0.720 $0.736 74 818
Jan 28, 2020 $0.790 $0.790 $0.705 $0.720 108 015
Jan 27, 2020 $0.740 $0.81 $0.700 $0.770 339 169
Jan 24, 2020 $0.81 $0.81 $0.720 $0.763 159 792
Jan 23, 2020 $0.790 $0.80 $0.755 $0.780 221 410
Jan 22, 2020 $0.81 $0.81 $0.760 $0.764 92 621
Jan 21, 2020 $0.80 $0.81 $0.750 $0.780 399 796
Jan 17, 2020 $0.718 $0.80 $0.700 $0.80 514 022
Jan 16, 2020 $0.720 $0.749 $0.710 $0.729 295 743
Jan 15, 2020 $0.725 $0.787 $0.725 $0.730 151 893
Jan 14, 2020 $0.81 $0.84 $0.713 $0.740 303 852
Jan 13, 2020 $0.92 $0.93 $0.700 $0.800 1 085 951
Jan 10, 2020 $0.769 $0.98 $0.765 $0.92 2 029 163
Jan 09, 2020 $0.773 $0.773 $0.723 $0.760 209 262
Jan 08, 2020 $0.700 $0.758 $0.680 $0.723 270 757
Jan 07, 2020 $0.660 $0.730 $0.657 $0.700 225 630
Jan 06, 2020 $0.650 $0.700 $0.650 $0.675 135 739
Jan 03, 2020 $0.672 $0.688 $0.615 $0.637 143 415
Jan 02, 2020 $0.670 $0.696 $0.666 $0.669 185 416
Dec 31, 2019 $0.720 $0.735 $0.645 $0.670 233 783
Dec 30, 2019 $0.585 $0.790 $0.575 $0.720 1 089 552
Dec 27, 2019 $0.560 $0.570 $0.531 $0.560 125 244
Click to get the best stock tips daily for free!

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-... CYCC Profile

Golden Star

Ticker Date Change Price
SXI May 08 2.97% $173.34
NVO May 08 1.37% $126.69
PAG May 07 1.42% $153.22
WMT May 06 1.02% $59.87
UNP May 06 3.42% $239.21
JPM May 06 3.53% $192.00
INGR May 03 4.94% $114.56
ASH May 03 2.28% $95.85
INVH May 03 1.13% $34.39
INTU May 03 0.483% $629.27
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT